ArticleMolecular cancer2014

Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance.

Daniele Cretella et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.